早期TOP2A正常乳腺癌辅助环磷酰胺联合多西他赛±表柔比星的III期随机试验DBCG 07-READ
这项多中心、开放标签、III期随机试验纳入2012例早期TOP2A正常且至少有一个高危因素的乳腺癌女性,随机接受6周期多西他赛+环磷酰胺(DC)或3周期表柔比星+环磷酰胺序贯3周期多西他赛(EC-D)。中位随访69个月,两组5年无病生存率无显著差异,风险比HR 1.00(95%CI 0.78-1.28,P=1.00)。结论支持在TOP2A正常早期乳腺癌中辅助蒽环类无总体结局获益。
要点
- 早期TOP2A正常乳腺癌中,DC与EC-D的5年DFS分别为88.3%与87.9%,无显著差异。
- DC组与EC-D组的总生存、无远处病生存风险均无显著差异。
- EC-D组口腔炎、肌痛/关节痛、呕吐、恶心、疲乏及周围神经病变报告显著更多,DC组水肿更常见。
核心结论
- 本研究证据支持在早期TOP2A正常乳腺癌患者中,辅助蒽环类治疗无总体结局获益。
研究设计与样本
- 多中心、开放标签、III期随机试验,纳入2012例早期TOP2A正常且至少有一个高危因素的乳腺癌女性。
- 随机分为6周期多西他赛75 mg/m2+环磷酰胺600 mg/m2每3周(DC)或3周期表柔比星90 mg/m2+环磷酰胺600 mg/m2序贯3周期多西他赛100 mg/m2(EC-D)。
- 主要终点为中位随访5年后的无病生存(DFS),次要终点为患者报告的毒性、总生存(OS)和无远处病生存。
主要发现
- 中位估计潜在随访69个月,EC-D组5年DFS为87.9%(95%CI 85.6%-89.8%),DC组为88.3%(95%CI 86.1%-90.1%)。
- 意向治疗分析中,DFS事件风险无显著差异(HR 1.00;95%CI 0.78-1.28;P=1.00),无远处病生存无显著差异(HR 1.12;95%CI 0.86-1.47;P=.40),死亡风险无显著差异(HR 1.15;95%CI 0.83-1.59;P=.41)。
- 绝经状态与治疗组对DFS存在显著交互作用(P=.04),对OS无显著交互作用(P=.07)。
- 3级肿瘤患者从DC获益最大,1-2级肿瘤患者从EC-D获益最大(DFS交互P=.02;OS交互P=.03)。
- EC-D组报告显著更多的口腔炎、肌痛或关节痛、呕吐、恶心、疲乏及周围神经病变,DC组水肿更频繁。
临床怎么用
- 原文结论为证据支持在早期TOP2A正常乳腺癌患者中辅助蒽环类无总体结局获益,未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Administration of anthracycline and taxane therapy in the adjuvant setting is considered a standard for breast cancer. We evaluated a non-anthracycline-based regimen in TOP2A-normal patients. Patients and Methods In this multicenter, open-label, phase III trial, 2,012 women with early TOP2A-normal breast cancer and at least one high-risk factor were randomly assigned to receive six cycles of docetaxel (75 mg/m2) and cyclophosphamide (600 mg/m2) every 3 weeks (DC) or three cycles of epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) followed by three cycles of docetaxel (100 mg/m2; EC-D). The primary end point was disease-free survival (DFS) after a median of 5 years of follow-up. Secondary end points were patient-reported toxicity, overall survival (OS), and distant disease-free survival. Results At a median estimated potential follow-up of 69 months, 5-year DFS was 87.9% (95% CI, 85.6% to 89.8%) in the EC-D arm and 88.3% (95% CI, 86.1% to 90.1%) in the DC arm. There was no significant difference in the risk of DFS events (hazard ratio [HR], 1.00; 95% CI, 0.78 to 1.28; P = 1.00), distant disease-free survival (HR, 1.12; 95% CI, 0.86 to 1.47; P = .40), or mortality (HR, 1.15; 95% CI, 0.83 to 1.59; P = .41) in the intent-to-treat analysis. A significant interaction between menopausal status and treatment group was observed for DFS ( P = .04) but not for OS ( P = .07). Patients with grade 3 tumors derived most benefit from DC, and patients with grade 1 to 2 tumors derived most benefit from EC-D (DFS: interaction P = .02; and OS: interaction P = .03). Patients receiving EC-D reported significantly more stomatitis, myalgia or arthralgia, vomiting, nausea, fatigue, and peripheral neuropathy, whereas edema was more frequent after DC. Conclusion This study provides evidence to support no overall outcome benefit from adjuvant anthracyclines in patients with early TOP2A-normal breast cancer.
引用
- Ejlertsen B, Tuxen MK, Jakobsen EH, et al. Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial. J Clin Oncol. 2017. PMID: 28661759. doi:10.1200/JCO.2017.72.3494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。